Erdheim-Chester disease: From palliative care to targeted treatment

Giorgio Graziani, Manuel A. Podestà, David Cucchiari, Francesco Reggiani, Claudio Ponticelli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Erdheim-Chester disease (ECD) is a life-threatening multi-systemic non-Langerhans histiocytosis with cardiovascular complications as the leading cause of death. ECD affects the kidneys in up to 30% of cases, with fibrotic tissue deposition in the perirenal fat and renal hilum. Diagnosis is usually based on histological analysis of the pathologic tissue, which typically shows xanthogranulomatous infiltrates of foamy CD68+/CD1a-histiocytes surrounded by fibrosis. A consistent percentage of patients affected by ECD develop renal failure and hypertension as a consequence of renal artery stenosis and hydronephrosis. These conditions have been generally treated with the placement of stents and nephrostomies that frequently led to disappointing outcomes. Before the introduction of interferon-alpha (IFNα) treatment, the mortality rate was as high as 57% in the long term. Recent studies have granted new insights into the pathogenesis of ECD, which seems to bear a dual component of clonal and inflammatory disease. These advances led to use specific therapies targeting either the oncogenes (BRAFV600E) or the effectors of the immune response implicated in ECD (IL-1, TNFα). Drugs such as anakinra (recombinant human IL-1 receptor antagonist), infliximab (monoclonal antibody against TNFα) and vemurafenib (inhibitor of mutant BRAF) showed promising results in small single-centre series. Although larger trials will be needed to address the impact of these drugs on ECD prognosis and to select the most effective treatment, targeted therapies hold the premises to drastically change the outcome of this condition.

Original languageEnglish
Pages (from-to)339-343
Number of pages5
JournalClinical Kidney Journal
Volume7
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Erdheim-Chester Disease
Palliative Care
Therapeutics
Histiocytosis
Interleukin 1 Receptor Antagonist Protein
Kidney
Renal Artery Obstruction
Renal Hypertension
Histiocytes
Interleukin-1 Receptors
Hydronephrosis
Interleukin-1
Oncogenes
Interferon-alpha
Pharmaceutical Preparations
Stents
Renal Insufficiency
Cause of Death
Fibrosis
Fats

Keywords

  • anakinra
  • Erdheim-Chester disease
  • infliximab
  • renal failure
  • vemurafenib

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Graziani, G., Podestà, M. A., Cucchiari, D., Reggiani, F., & Ponticelli, C. (2014). Erdheim-Chester disease: From palliative care to targeted treatment. Clinical Kidney Journal, 7(4), 339-343. https://doi.org/10.1093/ckj/sfu068

Erdheim-Chester disease : From palliative care to targeted treatment. / Graziani, Giorgio; Podestà, Manuel A.; Cucchiari, David; Reggiani, Francesco; Ponticelli, Claudio.

In: Clinical Kidney Journal, Vol. 7, No. 4, 2014, p. 339-343.

Research output: Contribution to journalArticle

Graziani, G, Podestà, MA, Cucchiari, D, Reggiani, F & Ponticelli, C 2014, 'Erdheim-Chester disease: From palliative care to targeted treatment', Clinical Kidney Journal, vol. 7, no. 4, pp. 339-343. https://doi.org/10.1093/ckj/sfu068
Graziani, Giorgio ; Podestà, Manuel A. ; Cucchiari, David ; Reggiani, Francesco ; Ponticelli, Claudio. / Erdheim-Chester disease : From palliative care to targeted treatment. In: Clinical Kidney Journal. 2014 ; Vol. 7, No. 4. pp. 339-343.
@article{e6545eefa11a4c378486dbf3ee09d0a7,
title = "Erdheim-Chester disease: From palliative care to targeted treatment",
abstract = "Erdheim-Chester disease (ECD) is a life-threatening multi-systemic non-Langerhans histiocytosis with cardiovascular complications as the leading cause of death. ECD affects the kidneys in up to 30{\%} of cases, with fibrotic tissue deposition in the perirenal fat and renal hilum. Diagnosis is usually based on histological analysis of the pathologic tissue, which typically shows xanthogranulomatous infiltrates of foamy CD68+/CD1a-histiocytes surrounded by fibrosis. A consistent percentage of patients affected by ECD develop renal failure and hypertension as a consequence of renal artery stenosis and hydronephrosis. These conditions have been generally treated with the placement of stents and nephrostomies that frequently led to disappointing outcomes. Before the introduction of interferon-alpha (IFNα) treatment, the mortality rate was as high as 57{\%} in the long term. Recent studies have granted new insights into the pathogenesis of ECD, which seems to bear a dual component of clonal and inflammatory disease. These advances led to use specific therapies targeting either the oncogenes (BRAFV600E) or the effectors of the immune response implicated in ECD (IL-1, TNFα). Drugs such as anakinra (recombinant human IL-1 receptor antagonist), infliximab (monoclonal antibody against TNFα) and vemurafenib (inhibitor of mutant BRAF) showed promising results in small single-centre series. Although larger trials will be needed to address the impact of these drugs on ECD prognosis and to select the most effective treatment, targeted therapies hold the premises to drastically change the outcome of this condition.",
keywords = "anakinra, Erdheim-Chester disease, infliximab, renal failure, vemurafenib",
author = "Giorgio Graziani and Podest{\`a}, {Manuel A.} and David Cucchiari and Francesco Reggiani and Claudio Ponticelli",
year = "2014",
doi = "10.1093/ckj/sfu068",
language = "English",
volume = "7",
pages = "339--343",
journal = "CKJ: Clinical Kidney Journal",
issn = "2048-8505",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Erdheim-Chester disease

T2 - From palliative care to targeted treatment

AU - Graziani, Giorgio

AU - Podestà, Manuel A.

AU - Cucchiari, David

AU - Reggiani, Francesco

AU - Ponticelli, Claudio

PY - 2014

Y1 - 2014

N2 - Erdheim-Chester disease (ECD) is a life-threatening multi-systemic non-Langerhans histiocytosis with cardiovascular complications as the leading cause of death. ECD affects the kidneys in up to 30% of cases, with fibrotic tissue deposition in the perirenal fat and renal hilum. Diagnosis is usually based on histological analysis of the pathologic tissue, which typically shows xanthogranulomatous infiltrates of foamy CD68+/CD1a-histiocytes surrounded by fibrosis. A consistent percentage of patients affected by ECD develop renal failure and hypertension as a consequence of renal artery stenosis and hydronephrosis. These conditions have been generally treated with the placement of stents and nephrostomies that frequently led to disappointing outcomes. Before the introduction of interferon-alpha (IFNα) treatment, the mortality rate was as high as 57% in the long term. Recent studies have granted new insights into the pathogenesis of ECD, which seems to bear a dual component of clonal and inflammatory disease. These advances led to use specific therapies targeting either the oncogenes (BRAFV600E) or the effectors of the immune response implicated in ECD (IL-1, TNFα). Drugs such as anakinra (recombinant human IL-1 receptor antagonist), infliximab (monoclonal antibody against TNFα) and vemurafenib (inhibitor of mutant BRAF) showed promising results in small single-centre series. Although larger trials will be needed to address the impact of these drugs on ECD prognosis and to select the most effective treatment, targeted therapies hold the premises to drastically change the outcome of this condition.

AB - Erdheim-Chester disease (ECD) is a life-threatening multi-systemic non-Langerhans histiocytosis with cardiovascular complications as the leading cause of death. ECD affects the kidneys in up to 30% of cases, with fibrotic tissue deposition in the perirenal fat and renal hilum. Diagnosis is usually based on histological analysis of the pathologic tissue, which typically shows xanthogranulomatous infiltrates of foamy CD68+/CD1a-histiocytes surrounded by fibrosis. A consistent percentage of patients affected by ECD develop renal failure and hypertension as a consequence of renal artery stenosis and hydronephrosis. These conditions have been generally treated with the placement of stents and nephrostomies that frequently led to disappointing outcomes. Before the introduction of interferon-alpha (IFNα) treatment, the mortality rate was as high as 57% in the long term. Recent studies have granted new insights into the pathogenesis of ECD, which seems to bear a dual component of clonal and inflammatory disease. These advances led to use specific therapies targeting either the oncogenes (BRAFV600E) or the effectors of the immune response implicated in ECD (IL-1, TNFα). Drugs such as anakinra (recombinant human IL-1 receptor antagonist), infliximab (monoclonal antibody against TNFα) and vemurafenib (inhibitor of mutant BRAF) showed promising results in small single-centre series. Although larger trials will be needed to address the impact of these drugs on ECD prognosis and to select the most effective treatment, targeted therapies hold the premises to drastically change the outcome of this condition.

KW - anakinra

KW - Erdheim-Chester disease

KW - infliximab

KW - renal failure

KW - vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84905190871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905190871&partnerID=8YFLogxK

U2 - 10.1093/ckj/sfu068

DO - 10.1093/ckj/sfu068

M3 - Article

AN - SCOPUS:84905190871

VL - 7

SP - 339

EP - 343

JO - CKJ: Clinical Kidney Journal

JF - CKJ: Clinical Kidney Journal

SN - 2048-8505

IS - 4

ER -